3.2 ︳Treatments and outcomes
Four preBLL patients were initially treated according to B-NHL/ALL protocols for mature B-cell leukemia from the beginning. Two courses of rituximab were administered to one of them because of the early termination of therapy for recurrent intracranial fungal abscess.
One patient received induction treatment according to protocols for BCP-ALL for 71 days and switched to B-NHL/ALL courses. In three patients, intensive treatment was followed by ALL-type maintenance therapy. Relapse occurred in one patient after 5 months since diagnosis, and the other four patients had maintained completed remission (CR) until the last follow-up. The other four patients were treated according to BCP-ALL protocol9, and two of them relapsed after 7 months and 19 months since diagnosis, respectively (Figure 1).